Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer.
Serum prostate-specific antigen is credited with dramatic advances in the early detection, screening, and management of men with prostatic carcinoma. There has been more than a twofold increase in the number of men diagnosed during the last decade, and prostate cancer has emerged as the most common non-skin cancer and the second leading cause of cancer death in men. This report summarizes the history and current status of prostate-specific antigen and other serum markers, incorporating consensus opinions from the Second International Consultation on Prostate Cancer held in Paris in June 1999.
Brawer
M K
MK
Northwest Prostate Institute, Pacific Northwest Cancer Foundation, Seattle, WA 98133, USA.
Benson
M C
MC
Bostwick
D G
DG
Djavan
B
B
Lilja
H
H
Semjonow
A
A
Su
S
S
Zhou
Z
Z
D000367:Age Factors; D000954:Antigens, Surface; D014408:Biomarkers, Tumor / Q000097:blood*; D002268:Carboxypeptidases / Q000097:blood; D043425:Glutamate Carboxypeptidase II; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D012016:Reference Values; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014944:World Health Organization
D000954:Antigens, Surface; D014408:Biomarkers, Tumor; D007334:Insulin-Like Growth Factor I; D002268:Carboxypeptidases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen